Join our daily newsletter At The Bell to receive exclusive market insights
Dimerix (ASX:DXB) has kicked off a key trial in Japan (in terms of patient recruitment) seeking to treat inflammatory diseases.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The company’s ACTION 3 trial stands for: “Angiotensin II Type 1 Receptor (AT1R) & Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis.”
It’s a Phase 3 trial looking at patients taking an angiotensin II receptor blocker and who present with a kidney disease called FSGS. Anybody who satisfies all of those requirements will be taking DXB’s “DMX200,” the flagship drug of interest being developed by Dimerix.
Phase 3 trials are the big kahunas when it comes to most countries’ health regulatory bureaucracies; indeed, the company is hoping the data it gets from ACTION3 ultimately locks in its path to a world where it can sell DMX200.
As part of its trial, Dimerix will also receive $4.3M from a partner on milestone grounds.
More market news
Trims: An RBA cut was locked. Beijing’s identical chop spotlights larger macro forces
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
“Opening the first clinical site in Japan is another major step forward for our global ACTION3 clinical program, as we aim to bring much-needed and new treatments to patients with FSGS around the world,” DXB CEO Dr. Nina Webster said.
“This milestone reflects the strength of our data to date, the rigour of our clinical trial design, and the expertise from our local partner in Japan, FUSO.”
DXB last traded at 58cps.
Join the discussion: See what HotCopper users are saying about Dimerix and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
